On the other hand, significant published data support the potential efficacy of AT1 receptor antagonists in animal models (see previous discussion), and several clinical trials of AT1 receptor blockers in IPF are currently underway [75]. Here, AGTR1 is linked to idiopathic pulmonary fibrosis.